STOCK TITAN

Akebia Therapeutics, Inc. (AKBA) Net Income by Year

AKBA

Akebia Therapeutics, Inc. reported a net loss of $5.3M in fiscal year 2025. This represents an increase of 92.4% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $29.6M net loss. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Akebia Therapeutics, Inc. has filed alongside them.

FY2025 annual
Net Income -$5.3M
YoY +92.4%
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

AKBA Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-K
Net Income-$29.6M-$5.3M+92.4%-$69.4M-33.7%-$51.9M+44.9%-$94.2M+66.6%-$282.0M+26.7%-$384.8M-37.6%-$279.7M-94.8%-$143.6M-94.9%-$73.7M+45.7%-$135.7M-123.6%-$60.7M-63.9%-$37.0M-181.3%-$13.2M-60.7%-$8.2M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

AKBA Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income-$8.9M-3706.5%-$9.1M-248.1%-$12.2M+46.5%$540K+102.7%$247K+102.9%$6.1M+134.0%-$22.8M-3678.3%-$20.0M-38.3%-$8.6M+23.2%-$18.0M+33.1%$637K+110.5%-$14.5M+73.2%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Akebia Therapeutics, Inc. financials

Frequently Asked Questions

What was Akebia Therapeutics, Inc.'s net income in fiscal year 2025?

Akebia Therapeutics, Inc. reported a net loss of $5.3M in fiscal year 2025.

How fast is Akebia Therapeutics, Inc.'s net income growing?

Akebia Therapeutics, Inc. (AKBA) net income rose by 92.4% year over year, from -$69.4M to -$5.3M in fiscal year 2025.

What is Akebia Therapeutics, Inc.'s net income over the last twelve months?

Akebia Therapeutics, Inc. (AKBA) reported a $29.6M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 14 fiscal years this page covers, Akebia Therapeutics, Inc. (AKBA) net income went from -$8.2M in fiscal year 2012 to -$5.3M in fiscal year 2025.

Akebia Therapeutics, Inc. (AKBA) reported -$8.9M in net income in Q2 2026. This represents a decrease of 3706.5% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Akebia Therapeutics, Inc. (AKBA) reported on that line in every period on record.